Australian diagnostics company Lumos Diagnostics announced this week that it has received US Food and Drug Administration (FDA) marketing clearance for a rapid diagnostic test that helps clinicians determine when antibiotics are needed for respiratory infections.
The FDA clearance means that FebriDX, a disposable point-of-care immunoassay designed to aid diagnosis of acute bacterial respiratory infections, can now be marketed in the United States for use by healthcare providers in urgent care and emergency care settings. Company officials say the test, which differentiates bacterial- from viral-associated host immune response and is intended to be used in conjunction with clinical signs and symptoms, could help improve antibiotic prescribing for acute respiratory infections.
We continue to believe it has an important role to play in antibiotic stewardship.
Although acute respiratory infections are predominantly viral in origin, they are the most common diagnosis for which outpatient antibiotics are prescribed.
"We are delighted to finally secure clearance to market our FebriDx rapid, point-of-care test in the US as we continue to believe it has an important role to play in antibiotic stewardship," said Lumos CEO Doug Ward in a company press release.
COVID-19 hospitalizations and deaths continue to decline, with levels down 5.9% and 9.1%, respectively, over the past week, the Centers for Disease Control and Prevention (CDC) said in its latest
Repeated antibiotic exposure may be associated with severe COVID-19 outcomes, British researchers reported this week in eClinical Medicine.
Data from hospitals in Chile, Brazil, and Argentina show substantial increases in intravenous antibiotic use at the beginning of the COVID-19 pandemic, researchers reported this week in Clinical Infectious Diseases.